1Life Healthcare, Inc. (One Medical) (Nasdaq: ONEM) today announced
financial results for the fourth quarter and full year ended
December 31, 2021.
“Last year at One Medical we significantly advanced our mission
to transform healthcare through our modernized primary care model,
reaching more people, in more markets, across every stage of life,"
said Amir Dan Rubin, Chair & CEO of One Medical. “We believe we
have never been better positioned to deliver better health, better
care, and better value, in a better team environment.”
Financial Highlights for the Fourth Quarter
2021
All comparisons are to the three months ended December 31,
2020. Unless otherwise noted, our results of operations in this
press release include the activity of Iora Health, Inc. ("Iora")
beginning from the close of our acquisition on September 1,
2021.
- Total membership
count as of quarter-end was 736,000 compared to 549,000, a 34%
increase; Consumer and Enterprise membership count of 703,000 and
At-Risk membership count of 33,000 as of quarter-end.
- Net Revenue was
$230.2 million compared to $121.8 million, an 89% increase.
- Medical Claims
Expense Ratio was 94%.
- Loss from
Operations was $95.8 million, or 42% of Net Revenue; Net Loss was
$95.4 million, or 41% of Net Revenue.
- Care Margin was
$37.6 million, or 16% of Net Revenue.
- Adjusted EBITDA
was a loss of $40.6 million, or 18% of Net Revenue.
Financial Highlights for the Full Year 2021
All comparisons are to the twelve months ended December 31,
2020. Unless otherwise noted, our results of operations in this
press release include the activity of Iora beginning from the close
of our acquisition on September 1, 2021.
- Net Revenue was
$623.3 million compared to $380.2 million, a 64% increase.
- Medical Claims
Expense Ratio was 92%.
- Loss from
Operations was $243.5 million, or 39% of Net Revenue; Net Loss was
$254.6 million, or 41% of Net Revenue.
- Care Margin was
$188.1 million, or 30% of Net Revenue.
- Adjusted EBITDA was a loss of $34.9 million, or 6% of Net
Revenue.
Financial Outlook
One Medical provides forward-looking guidance on membership
count, total net revenue, Care Margin, and Adjusted EBITDA. Care
Margin and Adjusted EBITDA are non-GAAP measures.
|
Three Months EndingMarch 31,
2022 |
|
Twelve Months EndingDecember 31,
2022 |
Amounts in millions,
except membership data |
Low |
|
High |
|
Low |
|
High |
Consumer and Enterprise Members |
|
715 |
|
|
|
735 |
|
|
|
790 |
|
|
|
810 |
|
At-Risk Members |
|
37 |
|
|
|
38 |
|
|
|
40 |
|
|
|
42 |
|
Total |
|
752 |
|
|
|
773 |
|
|
|
830 |
|
|
|
852 |
|
Medicare Revenue |
$ |
125 |
|
|
$ |
130 |
|
|
$ |
515 |
|
|
$ |
535 |
|
Commercial Revenue |
|
115 |
|
|
|
120 |
|
|
|
530 |
|
|
|
550 |
|
Total Net Revenue |
$ |
240 |
|
|
$ |
250 |
|
|
$ |
1,045 |
|
|
$ |
1,085 |
|
Care Margin |
$ |
35 |
|
|
$ |
45 |
|
|
$ |
195 |
|
|
$ |
215 |
|
Adjusted EBITDA |
$ |
(40 |
) |
|
$ |
(30 |
) |
|
$ |
(135 |
) |
|
$ |
(115 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Management has not reconciled forward-looking non-GAAP Care
Margin and Adjusted EBITDA to their most directly comparable GAAP
measures of loss from operations and net loss, respectively. This
is because we cannot predict with reasonable certainty and without
unreasonable efforts the ultimate outcome of certain GAAP
components of such reconciliations, including market-related
assumptions that are not within our control, certain legal or
advisory costs or others that may arise, without unreasonable
effort. For these reasons, we are unable to assess the probable
significance of the unavailable information, which could materially
impact the amount of the future directly comparable GAAP measures.
See below for additional important disclosures regarding our
non-GAAP financial measures.
Quarterly Conference Call Details
The company will host a conference call to review the results
today, Wednesday, February 23, 2022 at 1:30 p.m. (PT) / 4:30
p.m. (ET). A live audio webcast will be available online at
https://investor.onemedical.com. The conference call can also be
accessed by dialing 1-800-258-1651 for U.S. participants, or
1-612-979-9928 for international participants, and referencing
conference ID 5176036. A replay of the call will be available via
webcast for on-demand listening shortly after the completion of the
call, at the same web link, and will remain available for
approximately 90 days.
Key Metrics and Non-GAAP Financial Measures
Members: members include both Consumer and
Enterprise members as well as At-Risk members as defined below. Our
number of members depends, in part, on our ability to successfully
market our services directly to consumers including
Medicare-eligible as well as non-Medicare eligible individuals, to
Medicare Advantage health plans and Medicare Advantage enrollees,
to employers that are not yet enterprise clients, as well as our
activation rate within existing enterprise clients. We define
estimated activation rate for any enterprise client at a given time
as the percentage of eligible lives enrolled as members. While
growth in the number of members is an important indicator of
expected revenue growth, it also informs our management of the
areas of our business that will require further investment to
support expected future member growth. Member numbers as of the end
of each period are rounded to the thousands.
Consumer and Enterprise
Members: a Consumer and Enterprise member
is a person who has registered with us and has paid for membership
for a period of at least one year or whose membership has been
sponsored by an enterprise or other third party under an agreement
having a term of at least one year. Consumer and Enterprise members
do not include trial memberships, our virtual only One Medical Now
users, or any temporary users. Our number of Consumer and
Enterprise members depends, in part, on our ability to successfully
market our services directly to consumers and to employers that are
not yet enterprise clients and our activation rate within existing
clients. Consumer and Enterprise members may include individuals
who are: (i) Medicare-eligible and (ii) have paid for a membership
or whose membership has been sponsored by an enterprise or other
third party. Consumer and Enterprise members do not include any
At-Risk members as defined below. Consumer and Enterprise members
help drive commercial revenue.
At-Risk
Members: an At-Risk member is a person
for whom we are responsible for managing a range of healthcare
services and associated costs. At-Risk members help drive Medicare
revenue.
Reconciliations of non-GAAP financial measures to the most
directly comparable financial results as determined in accordance
with GAAP are included at the end of this press release following
the accompanying financial data. We believe that these non-GAAP
financial measures, when taken together with the corresponding GAAP
financial measures, provide meaningful supplemental information
regarding our performance by excluding certain items that may not
be indicative of our business, results of operations, or outlook.
However, non-GAAP financial information is presented for
supplemental informational purposes only, has limitations as an
analytical tool and should not be considered in isolation or as a
substitute for financial information presented in accordance with
GAAP. In addition, other companies, including companies in our
industry, may calculate similarly-titled non-GAAP measures
differently or may use other measures to evaluate their
performance, all of which could reduce the usefulness of our
non-GAAP financial measures as tools for comparison.
Medical Claims Expense Ratio: we define Medical
Claims Expense Ratio as medical claims expense divided by Capitated
Revenue. The nature of our contracting with Medicare Advantage
payers and CMS requires us to be financially responsible for a
range of healthcare services of our At-Risk members. Our care model
focuses on leveraging the primary care setting as a means of
reducing unnecessary or avoidable health care costs and balancing
our cost of care with the impact of our service levels on medical
claims expense. We are liable for potentially large medical claims
should we not effectively manage our At-Risk members’ health. We
therefore consider the Medical Claims Expense Ratio to be an
important measure to monitor our performance. As we sign up new
At-Risk members or open new offices to serve these members, our
Medical Claims Expense Ratio is likely to increase initially due to
a potential increase in medical claims expense from a lag in
improvement in health outcomes with member tenure. Similarly, there
may be a lag in adequately documenting the health status of our
members, resulting in different Capitated Revenue compared to what
is indicated by the health status of an At-Risk member. We believe
that the Medical Claims Expense Ratio for a given set of At-Risk
members can improve over time as we help improve their health
outcomes relative to their underlying health conditions.
Care Margin: we define Care Margin as income or
loss from operations excluding depreciation and amortization,
general and administrative expense and sales and marketing expense.
We consider Care Margin to be an important measure to monitor our
performance, specific to the direct costs of delivering
care. We believe this margin is useful to both us and
investors to measure whether we are effectively pricing our
services and managing the health care and associated costs,
including medical claims expense and cost of care, of our At-Risk
members successfully. We have provided below a reconciliation of
historical Care Margin to loss from operations, its most directly
comparable GAAP financial measure.
Adjusted EBITDA: we define Adjusted EBITDA as
net income or loss excluding interest income, interest and other
expense, depreciation and amortization, stock-based compensation,
change in the fair value of our redeemable convertible preferred
stock warrant liability, provision for (benefit from) income taxes,
certain legal or advisory costs, and acquisition and integration
costs that we do not consider to be expenses incurred in the normal
operation of the business. Such legal or advisory costs may include
but are not limited to expenses with respect to evaluating
potential business combinations, legal investigations, or
settlements. Acquisition and integration costs include expenses
incurred in connection with the closing and integration of
acquisitions, which may vary significantly and are unique to each
acquisition. We started to exclude prospectively from our
presentation certain legal or advisory costs from the first quarter
of 2021 and acquisition and integration costs from the second
quarter of 2021, because amounts incurred in the prior periods were
insignificant relative to our consolidated operations. We include
Adjusted EBITDA because it is an important measure upon which our
management assesses and believes investors should assess our
operating performance. We consider Adjusted EBITDA to be an
important measure to both management and investors because it helps
illustrate underlying trends in our business and our historical
operating performance on a more consistent basis. We have provided
below a reconciliation of historical Adjusted EBITDA to net loss,
its most directly comparable GAAP financial measure.
Available Information
One Medical intends to use its Company website (including its
Investor Relations website) as well as its Facebook, Twitter and
LinkedIn accounts as a means of disclosing material non-public
information and for complying with its disclosure obligations under
Regulation FD.
Forward-Looking Statements
This press release contains forward-looking statements about us
and our industry that involve substantial risks and uncertainties
and are based on our beliefs and assumptions and on information
currently available to us. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations, financial
condition, business strategy and plans and objectives of management
for future operations, are forward-looking statements. In some
cases, you can identify forward-looking statements because they
contain words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” or “would,” or the negative of these
words or other similar terms or expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Forward-looking statements
represent our current beliefs, estimates and assumptions only as of
the date of this press release and information contained in this
press release should not be relied upon as representing our
estimates as of any subsequent date. These statements, and related
risks, uncertainties, factors and assumptions, include, but are not
limited to: timely and successful integration of Iora with our
company and our ability to timely and successfully achieve the
anticipated benefits and potential synergies of the transaction;
the strength of the One Medical brand; member satisfaction with our
services and support; the effects of the COVID-19 pandemic,
including any new outbreaks and emerging variant strains of the
virus, and related self-isolation and quarantine measures on our
business, revenue, future growth and results of operations;
anticipated membership growth and revenue potential from our
members; our ability to retain members; our ability to successfully
introduce and drive adoption of new products; changes in the
pricing we offer our members; our relationships with our health
network partners and enterprise clients and any changes to,
accommodations in or terminations of our contracts with the health
network partners or enterprise clients; our ability to improve cost
of care and margins, including timing and expenses of new office
openings and entry into new geographic markets; changes in laws or
regulations; our involvement in existing and potential litigation,
including medical malpractice claims and consumer class actions;
any governmental investigations or inquiries, including those
related to COVID-19 vaccine administration or challenges to our
relationships with the One Medical PCs under the administrative
services agreements; our strategic plan; the impact of new laws and
regulations on our industry, including Medicare, general economic
and market conditions, our financial outlook; our focus areas for
investment and our investments; announcements by us or our
competitors of business or strategic developments; and our overall
business trajectory. These risks are not exhaustive. Except as
required by law, we assume no obligation to update these
forward-looking statements, or to update the reasons actual results
could differ materially from those anticipated in the
forward-looking statements, even if new information becomes
available in the future. Further information on factors that could
cause actual results to differ materially from the results
anticipated by our forward-looking statements is included in the
reports we have filed or will file with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year
ended December 31, 2021. These filings, when available, are
available on the investor relations section of our website at
investor.onemedical.com and on the SEC’s website at
www.sec.gov.
About One Medical
One Medical is a membership-based and technology-powered primary
care platform with seamless digital health and inviting in-office
care, convenient to where people work, shop, live, and click. Our
vision is to delight millions of members with better health and
better care while reducing costs. Our mission is to transform
health care for all through our human-centered, technology-powered
model. Headquartered in San Francisco, 1Life Healthcare, Inc. is
the administrative and managerial services company for the
affiliated One Medical physician owned professional corporations
that deliver medical services in-office and virtually. 1Life and
the One Medical entities do business under the “One Medical”
brand.
Media Contact:Kristina Skinner, One
MedicalSenior Director of External
Communicationspress@onemedical.com
Investor Contact:Ken Goff, One MedicalVP of
Investor Relationsinvestor@onemedical.com
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS(Amounts in thousands, except per share
amounts)(unaudited)
|
Three Months Ended December 31, |
|
Year Ended December 31 |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Net revenue: |
|
|
|
|
|
|
|
Medicare revenue |
$ |
99,517 |
|
|
$ |
— |
|
|
$ |
129,979 |
|
|
$ |
— |
|
Commercial revenue |
|
130,697 |
|
|
|
121,800 |
|
|
|
493,336 |
|
|
|
380,223 |
|
Total net revenue |
|
230,214 |
|
|
|
121,800 |
|
|
|
623,315 |
|
|
|
380,223 |
|
Operating expenses: |
|
|
|
|
|
|
|
Medical claims expense |
|
90,458 |
|
|
|
— |
|
|
|
116,543 |
|
|
|
— |
|
Cost of care, exclusive of depreciation and amortization shown
separately below |
|
102,182 |
|
|
|
71,179 |
|
|
|
318,639 |
|
|
|
234,959 |
|
Sales and marketing (1) |
|
24,355 |
|
|
|
8,120 |
|
|
|
61,994 |
|
|
|
36,967 |
|
General and administrative (1) |
|
88,516 |
|
|
|
39,046 |
|
|
|
323,127 |
|
|
|
157,282 |
|
Depreciation and amortization |
|
20,552 |
|
|
|
6,251 |
|
|
|
46,496 |
|
|
|
22,374 |
|
Total operating expenses |
|
326,063 |
|
|
|
124,596 |
|
|
|
866,799 |
|
|
|
451,582 |
|
Loss from operations |
|
(95,849 |
) |
|
|
(2,796 |
) |
|
|
(243,484 |
) |
|
|
(71,359 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
Interest income |
|
79 |
|
|
|
174 |
|
|
|
798 |
|
|
|
1,809 |
|
Interest and other expense |
|
(3,608 |
) |
|
|
(5,758 |
) |
|
|
(13,757 |
) |
|
|
(13,434 |
) |
Change in fair value of redeemable convertible preferred stock
warrant liability |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6,560 |
) |
Total other income (expense), net |
|
(3,529 |
) |
|
|
(5,584 |
) |
|
|
(12,959 |
) |
|
|
(18,185 |
) |
Loss before income taxes |
|
(99,378 |
) |
|
|
(8,380 |
) |
|
|
(256,443 |
) |
|
|
(89,544 |
) |
Provision for (benefit from)
income taxes |
|
(3,945 |
) |
|
|
(232 |
) |
|
|
(1,802 |
) |
|
|
(123 |
) |
Net loss |
|
(95,433 |
) |
|
|
(8,148 |
) |
|
|
(254,641 |
) |
|
|
(89,421 |
) |
Less: Net loss attributable to noncontrolling interest |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(704 |
) |
Net loss attributable to 1Life
Healthcare, Inc. stockholders |
$ |
(95,433 |
) |
|
$ |
(8,148 |
) |
|
$ |
(254,641 |
) |
|
$ |
(88,717 |
) |
Net loss per share
attributable to 1Life Healthcare, Inc. stockholders - basic and
diluted |
$ |
(0.50 |
) |
|
$ |
(0.06 |
) |
|
$ |
(1.64 |
) |
|
$ |
(0.75 |
) |
Weighted average common shares
outstanding - basic and diluted |
|
192,402 |
|
|
|
133,533 |
|
|
|
155,343 |
|
|
|
118,379 |
|
(1) Includes stock-based compensation, as
follows:
|
Three Months Ended December 31, |
|
Year Ended December 31 |
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
Sales and marketing |
$ |
1,265 |
|
$ |
542 |
|
$ |
4,136 |
|
$ |
2,385 |
General and administrative |
|
29,839 |
|
|
7,230 |
|
|
108,162 |
|
|
32,710 |
Total |
$ |
31,104 |
|
$ |
7,772 |
|
$ |
112,298 |
|
$ |
35,095 |
Components of Net Revenue:
|
Three Months Ended December 31, |
|
Year Ended December 31 |
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
Net revenue: |
|
|
|
|
|
|
|
Capitated revenue |
$ |
96,737 |
|
$ |
— |
|
$ |
126,609 |
|
$ |
— |
Fee-for-service and other revenue |
|
2,780 |
|
|
— |
|
|
3,370 |
|
|
— |
Total Medicare revenue |
|
99,517 |
|
|
— |
|
|
129,979 |
|
|
— |
Partnership revenue |
|
58,447 |
|
|
52,117 |
|
|
224,051 |
|
|
159,482 |
Net fee-for-service revenue |
|
49,098 |
|
|
51,438 |
|
|
181,811 |
|
|
149,695 |
Membership revenue |
|
23,152 |
|
|
18,245 |
|
|
85,711 |
|
|
68,466 |
Grant income |
|
— |
|
|
— |
|
|
1,763 |
|
|
2,580 |
Total commercial revenue |
|
130,697 |
|
|
121,800 |
|
|
493,336 |
|
|
380,223 |
Total net revenue |
$ |
230,214 |
|
$ |
121,800 |
|
$ |
623,315 |
|
$ |
380,223 |
Statements of Operations Data as a Percentage of Net
Revenue:
|
Three Months Ended December 31, |
|
Year Ended December 31 |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
Net revenue: |
|
|
|
|
|
|
|
Medicare revenue |
43 |
% |
|
— |
% |
|
21 |
% |
|
— |
% |
Commercial revenue |
57 |
% |
|
100 |
% |
|
79 |
% |
|
100 |
% |
Total net revenue |
100 |
% |
|
100 |
% |
|
100 |
% |
|
100 |
% |
Operating expenses: |
|
|
|
|
|
|
|
Medical claims expense |
39 |
% |
|
— |
% |
|
19 |
% |
|
— |
% |
Cost of care, exclusive of depreciation and amortization shown
separately below |
44 |
% |
|
58 |
% |
|
51 |
% |
|
62 |
% |
Sales and marketing (1) |
11 |
% |
|
7 |
% |
|
10 |
% |
|
10 |
% |
General and administrative (1) |
38 |
% |
|
32 |
% |
|
52 |
% |
|
41 |
% |
Depreciation and amortization |
9 |
% |
|
5 |
% |
|
7 |
% |
|
6 |
% |
Total operating expenses |
142 |
% |
|
102 |
% |
|
139 |
% |
|
119 |
% |
Loss from operations |
(42)% |
|
(2)% |
|
(39)% |
|
(19)% |
Other income (expense), net: |
|
|
|
|
|
|
|
Interest income |
— |
% |
|
— |
% |
|
— |
% |
|
— |
% |
Interest and other expense |
(2)% |
|
(5)% |
|
(2)% |
|
(4)% |
Change in fair value of redeemable convertible preferred stock
warrant liability |
— |
% |
|
— |
% |
|
— |
% |
|
(2)% |
Total other income (expense), net |
(2)% |
|
(5)% |
|
(2)% |
|
(5)% |
Loss before income taxes |
(43)% |
|
(7)% |
|
(41)% |
|
(24)% |
Provision for (benefit from)
income taxes |
(2)% |
|
— |
% |
|
— |
% |
|
— |
% |
Net loss |
(41)% |
|
(7)% |
|
(41)% |
|
(24)% |
Less: Net loss attributable to noncontrolling interest |
— |
% |
|
— |
% |
|
— |
% |
|
— |
% |
Net loss attributable to 1Life
Healthcare, Inc. stockholders |
(41)% |
|
(7)% |
|
(41)% |
|
(23) % |
(1) Includes stock-based compensation, as
follows:
|
Three Months Ended December 31, |
|
Year Ended December 31 |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
Sales and marketing |
1 |
% |
|
— |
% |
|
1 |
% |
|
1 |
% |
General and administrative |
13 |
% |
|
6 |
% |
|
17 |
% |
|
9 |
% |
Total |
14 |
% |
|
6 |
% |
|
18 |
% |
|
9 |
% |
Components of Net Revenue:
|
Three Months Ended December 31, |
|
Year Ended December 31 |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
Net revenue: |
|
|
|
|
|
|
|
Capitated revenue |
42 |
% |
|
— |
% |
|
20 |
% |
|
— |
% |
Fee-for-service and other revenue |
1 |
% |
|
— |
% |
|
1 |
% |
|
— |
% |
Total Medicare revenue |
43 |
% |
|
— |
% |
|
21 |
% |
|
— |
% |
Partnership revenue |
25 |
% |
|
43 |
% |
|
36 |
% |
|
42 |
% |
Net fee-for-service revenue |
21 |
% |
|
42 |
% |
|
29 |
% |
|
39 |
% |
Membership revenue |
10 |
% |
|
15 |
% |
|
14 |
% |
|
18 |
% |
Grant income |
— |
% |
|
— |
% |
|
— |
% |
|
1 |
% |
Total commercial revenue |
57 |
% |
|
100 |
% |
|
79 |
% |
|
100 |
% |
Total net revenue |
100 |
% |
|
100 |
% |
|
100 |
% |
|
100 |
% |
*Percentages may not sum due to rounding.
CONDENSED CONSOLIDATED BALANCE
SHEETS(Amounts in thousands, except par value
amounts)(unaudited)
|
December 31, |
|
|
2021 |
|
|
|
2020 |
|
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
341,971 |
|
|
$ |
112,975 |
|
Short-term marketable securities |
|
111,671 |
|
|
|
570,023 |
|
Accounts receivable, net |
|
103,498 |
|
|
|
67,895 |
|
Inventories |
|
6,065 |
|
|
|
7,113 |
|
Prepaid expenses |
|
28,055 |
|
|
|
9,169 |
|
Other current assets |
|
21,767 |
|
|
|
7,524 |
|
Total current assets |
|
613,027 |
|
|
|
774,699 |
|
Long-term marketable securities |
|
48,296 |
|
|
|
— |
|
Restricted cash |
|
3,801 |
|
|
|
1,911 |
|
Property and equipment, net |
|
193,716 |
|
|
|
126,037 |
|
Right-of-use assets |
|
256,293 |
|
|
|
138,840 |
|
Intangible assets, net |
|
352,158 |
|
|
|
— |
|
Goodwill |
|
1,147,464 |
|
|
|
21,301 |
|
Deferred income taxes |
|
— |
|
|
|
2,656 |
|
Other assets |
|
12,277 |
|
|
|
5,546 |
|
Total assets |
$ |
2,627,032 |
|
|
$ |
1,070,990 |
|
Liabilities and
Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
18,725 |
|
|
$ |
12,654 |
|
Accrued expenses |
|
72,672 |
|
|
|
46,527 |
|
Deferred revenue, current |
|
47,928 |
|
|
|
35,966 |
|
Operating lease liabilities, current |
|
31,152 |
|
|
|
17,418 |
|
Other current liabilities |
|
31,632 |
|
|
|
4,861 |
|
Total current liabilities |
|
202,109 |
|
|
|
117,426 |
|
Operating lease liabilities,
non-current |
|
269,641 |
|
|
|
153,614 |
|
Convertible senior notes |
|
309,844 |
|
|
|
241,233 |
|
Deferred income taxes |
|
73,875 |
|
|
|
— |
|
Deferred revenue,
non-current |
|
29,317 |
|
|
|
7,624 |
|
Other non-current
liabilities |
|
13,663 |
|
|
|
2,618 |
|
Total liabilities |
|
898,449 |
|
|
|
522,515 |
|
Commitments and
contingencies |
|
|
|
Stockholders' Equity: |
|
|
|
Common stock, $0.001 par value, 1,000,000 and 1,000,000 shares
authorized as of December 31, 2021 and December 31, 2020,
respectively; 191,722 and 134,472 shares issued and outstanding as
of December 31, 2021 and December 31, 2020,
respectively |
|
193 |
|
|
|
134 |
|
Additional paid-in capital |
|
2,346,781 |
|
|
|
918,118 |
|
Accumulated deficit |
|
(618,198 |
) |
|
|
(369,785 |
) |
Accumulated other comprehensive income |
|
(193 |
) |
|
|
8 |
|
Total stockholders' equity |
|
1,728,583 |
|
|
|
548,475 |
|
Total liabilities and stockholders' equity |
$ |
2,627,032 |
|
|
$ |
1,070,990 |
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS(Amounts in
thousands)(unaudited)
|
Year Ended December 31 |
|
|
2021 |
|
|
|
2020 |
|
Cash flows from operating
activities: |
|
|
|
Net loss |
$ |
(254,641 |
) |
|
$ |
(89,421 |
) |
Adjustments to reconcile net loss
to net cash used in operating activities: |
|
|
|
Provision for bad debts |
|
966 |
|
|
|
105 |
|
Depreciation and amortization |
|
46,496 |
|
|
|
22,374 |
|
Amortization of debt discount and issuance costs |
|
1,874 |
|
|
|
7,767 |
|
Accretion of discounts and amortization of premiums on marketable
securities, net |
|
1,178 |
|
|
|
(933 |
) |
Change in fair value of redeemable convertible preferred stock
warrant liability |
|
— |
|
|
|
6,560 |
|
Reduction of operating lease right-of-use assets |
|
22,062 |
|
|
|
13,653 |
|
Stock-based compensation |
|
112,298 |
|
|
|
35,095 |
|
Deferred income taxes |
|
(4,006 |
) |
|
|
(2,656 |
) |
Other non-cash items |
|
864 |
|
|
|
(8 |
) |
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable, net |
|
(16,546 |
) |
|
|
(35,167 |
) |
Inventories |
|
1,118 |
|
|
|
(3,921 |
) |
Prepaid expenses and other current assets |
|
(18,979 |
) |
|
|
6,488 |
|
Other assets |
|
1,687 |
|
|
|
(943 |
) |
Accounts payable |
|
3,111 |
|
|
|
298 |
|
Accrued expenses |
|
11,175 |
|
|
|
26,849 |
|
Deferred revenue |
|
3,350 |
|
|
|
16,566 |
|
Operating lease liabilities |
|
(20,919 |
) |
|
|
(12,169 |
) |
Other liabilities |
|
20,346 |
|
|
|
5,085 |
|
Net cash used in operating activities |
|
(88,566 |
) |
|
|
(4,378 |
) |
Cash flows from investing
activities: |
|
|
|
Purchases of property and
equipment, net |
|
(63,616 |
) |
|
|
(63,707 |
) |
Purchases of marketable
securities |
|
(215,289 |
) |
|
|
(963,272 |
) |
Proceeds from sales and
maturities of marketable securities |
|
623,966 |
|
|
|
513,315 |
|
Acquisitions of businesses, net
of cash and restricted cash acquired |
|
(23,257 |
) |
|
|
— |
|
Issuance of note receivable |
|
(30,000 |
) |
|
|
— |
|
VIE deconsolidation |
|
— |
|
|
|
(810 |
) |
Net cash provided by (used in) investing activities |
|
291,804 |
|
|
|
(514,474 |
) |
Cash flows from financing
activities: |
|
|
|
Proceeds from issuance of
convertible senior notes |
|
— |
|
|
|
316,250 |
|
Payment of convertible senior
notes issuance costs |
|
— |
|
|
|
(9,374 |
) |
Proceeds from initial public
offering |
|
— |
|
|
|
281,750 |
|
Payment of underwriting discount
and commissions, and offering costs |
|
— |
|
|
|
(20,538 |
) |
Proceeds from the exercise of
stock options |
|
22,784 |
|
|
|
35,686 |
|
Proceeds from employee stock
purchase plan |
|
5,078 |
|
|
|
4,835 |
|
Taxes paid related to net share
settlement of equity awards |
|
— |
|
|
|
(833 |
) |
Proceeds from the exercise of
redeemable convertible preferred and common stock warrants |
|
— |
|
|
|
110 |
|
Repayment of notes payable |
|
— |
|
|
|
(3,300 |
) |
Payment of principal portion of
finance lease liability |
|
(51 |
) |
|
|
(58 |
) |
Net cash provided by financing activities |
|
27,811 |
|
|
|
604,528 |
|
Net increase in cash,
cash equivalents and restricted cash |
|
231,049 |
|
|
|
85,676 |
|
Cash, cash equivalents and
restricted cash at beginning of period |
|
115,005 |
|
|
|
29,329 |
|
Cash, cash equivalent and
restricted cash at end of period |
$ |
346,054 |
|
|
$ |
115,005 |
|
Supplemental disclosure
of cash flow information: |
|
|
|
Cash paid for income taxes |
$ |
13,177 |
|
|
$ |
— |
|
Cash paid for interest |
$ |
9,495 |
|
|
$ |
5,251 |
|
Supplemental disclosure
of non-cash investing and financing activities: |
|
|
|
Purchases of property and
equipment included in accounts payable and accrued expenses |
$ |
10,707 |
|
|
$ |
4,571 |
|
Equity consideration provided for
business acquisition |
$ |
1,361,955 |
|
|
$ |
— |
|
Select Metrics (As of Period
End)
|
|
December 31,2021 |
|
September 30,2021 |
|
June 30,2021 |
|
March 31,2021 |
|
December 31,2020 |
|
September 30,2020 |
|
June 30,2020 |
|
March 31,2020 |
Consumer and Enterprise
members |
|
703,000 |
|
683,000 |
|
621,000 |
|
598,000 |
|
549,000 |
|
511,000 |
|
475,000 |
|
455,000 |
At-Risk members |
|
33,000 |
|
32,000 |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
Offices |
|
182 |
|
177 |
|
124 |
|
110 |
|
107 |
|
103 |
|
96 |
|
92 |
MEDICAL CLAIMS EXPENSE RATIO
|
|
Three Months EndedDecember
31, |
|
Year Ended December 31 |
|
|
|
2021 |
|
|
|
2020 |
|
|
2021 |
|
|
|
2020 |
|
|
(in thousands) |
Medical claims expense |
|
$ |
90,458 |
|
|
$ |
— |
|
$ |
116,543 |
|
|
$ |
— |
Capitated Revenue |
|
$ |
96,737 |
|
|
$ |
— |
|
$ |
126,609 |
|
|
$ |
— |
Medical Claims Expense
Ratio |
|
|
94 |
% |
|
N/A |
|
|
92 |
% |
|
N/A |
RECONCILIATION OF LOSS FROM OPERATIONS TO
CARE MARGIN
|
Three Months EndedDecember
31, |
|
Year Ended December 31 |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
(in thousands) |
Loss from
operations |
$ |
(95,849 |
) |
|
$ |
(2,796 |
) |
|
$ |
(243,484 |
) |
|
$ |
(71,359 |
) |
Sales and marketing* |
|
24,355 |
|
|
|
8,121 |
|
|
|
61,994 |
|
|
|
36,967 |
|
General and administrative* |
|
88,516 |
|
|
|
39,046 |
|
|
|
323,127 |
|
|
|
157,282 |
|
Depreciation and amortization |
|
20,552 |
|
|
|
6,251 |
|
|
|
46,496 |
|
|
|
22,374 |
|
Care
margin |
$ |
37,574 |
|
|
$ |
50,622 |
|
|
$ |
188,133 |
|
|
$ |
145,264 |
|
Care margin as a percentage of
net revenue |
|
16 |
% |
|
|
42 |
% |
|
|
30 |
% |
|
|
38 |
% |
*
Includes stock-based compensation |
RECONCILIATION OF NET LOSS TO ADJUSTED
EBITDA
|
Three Months EndedDecember
31, |
|
Year Ended December 31 |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
(in thousands) |
Net loss |
$ |
(95,433 |
) |
|
$ |
(8,147 |
) |
|
$ |
(254,641 |
) |
|
$ |
(89,421 |
) |
Interest income |
|
(79 |
) |
|
|
(173 |
) |
|
|
(798 |
) |
|
|
(1,809 |
) |
Interest and other
expense |
|
3,608 |
|
|
|
5,757 |
|
|
|
13,757 |
|
|
|
13,434 |
|
Depreciation and
amortization |
|
20,552 |
|
|
|
6,251 |
|
|
|
46,496 |
|
|
|
22,374 |
|
Stock-based compensation |
|
31,104 |
|
|
|
7,772 |
|
|
|
112,298 |
|
|
|
35,095 |
|
Change in fair value of
redeemable convertible preferred stock warrant liability |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,560 |
|
Provision for (benefit from)
income taxes |
|
(3,945 |
) |
|
|
(233 |
) |
|
|
(1,802 |
) |
|
|
(123 |
) |
Legal or advisory costs (1) (2) |
|
426 |
|
|
|
— |
|
|
|
16,514 |
|
|
|
— |
|
Acquisition and integration
costs |
|
3,205 |
|
|
|
— |
|
|
|
33,318 |
|
|
|
— |
|
Adjusted
EBITDA |
$ |
(40,562 |
) |
|
$ |
11,227 |
|
|
$ |
(34,858 |
) |
|
$ |
(13,890 |
) |
(1) |
Approximately $5.6 million of the legal or advisory costs relate to
a legal settlement during the year ended December 31,
2021. |
|
|
(2) |
Amount excludes approximately
$1.2 million of legal or advisory costs incurred during the year
ended December 31, 2020. We began excluding certain legal or
advisory costs from Adjusted EBITDA starting from the first quarter
of 2021. |
1Life Healthcare (NASDAQ:ONEM)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
1Life Healthcare (NASDAQ:ONEM)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025